HRTX · XBRL financial data

Heron Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	36	46	55	65	39	41
Gross profit	—	—	53	62	106	114
Research and development	175	131	108	56	17	12
General and administrative	42	40	37	49	53	55
Operating income (loss)	(228)	(218)	(175)	(111)	(12)	(3)
Interest income	4	0	2	3	4	2
Interest expense	2	2	2	4	6	10
Other income (expense)	(1)	(1)	(7)	1	0	1
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(227)	(221)	(182)	(111)	(14)	(20)
Earnings per share, basic USD per share	—	(2.24)	(1.67)	(0.80)	(0.09)	(0.12)
Earnings per share, diluted USD per share	—	(2.24)	(1.67)	(0.80)	(0.09)	(0.12)
Weighted average shares, basic millions of shares	—	0	0	138	152	167
Weighted average shares, diluted millions of shares	—	0	0	138	152	167

Fiscal years (HRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	105	91	15	29	26	29
Marketable securities	103	67	69	52	33	18
Accounts receivable	42	35	52	60	79	90
Inventory	42	48	55	42	53	93
Prepaid and other current assets	22	13	14	6	18	9
Total current assets	314	254	205	189	209	238
Property and equipment, net	23	24	22	20	15	12
Right-of-use asset	16	10	8	5	3	0
Total assets	354	306	251	223	233	256
Accounts payable	1	4	3	3	12	9
Total current liabilities	103	71	82	80	91	96
Lease liability, non-current	15	8	5	3	—	0
Total liabilities	117	228	237	256	267	242
Accumulated deficit	(1,393)	(1,613)	(1,795)	(1,906)	(1,920)	(1,940)
Total stockholders' equity	236	78	14	(34)	(34)	14
Total liabilities and equity	354	306	251	223	233	256
Common shares outstanding (cover page) millions of shares	91	102	119	150	152	189

Fiscal years (HRTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(227)	(221)	(182)	(111)	(14)	(20)
Stock-based compensation	50	47	43	33	13	10
Depreciation and amortization	3	3	3	3	2	2
Net cash from operating activities	(185)	(203)	(147)	(59)	(23)	(28)
Purchases of property and equipment	7	3	2	2	2	0
Net cash from investing activities	209	33	(3)	18	19	16
Proceeds from issuing common stock	—	—	75	30	—	18
Net cash from financing activities	9	156	75	54	1	14
Net change in cash	33	(15)	(75)	13	(3)	3

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Heron Therapeutics	21	not reported	(2.2)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199	not reported	(48)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	23	25	6.9*	37.9M	—	Q3 FY26 10-QSep 30, 2026
DBV Technologies	166	1.6	(52)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	19	not reported	(15)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16	55	(18)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.